All posts by imreal

Pacific Group Breaks Ground on Multi-million Dollar Medical Campus in North Las Vegas


Today, the development team from Pacific Group and community leaders from the City of North Las Vegas officially broke ground on the new Helios Health and Wellness Campus, kicking off a new era of economic development and job creation that will result in a transformative campus and economic hub to serve the growing population of North Las Vegas.

“Today’s historic groundbreaking of the Helios Health and Wellness Campus ushers in a new era of medical care in North Las Vegas, Southern Nevada, and the entire Southwest region,” North Las Vegas Mayor John Lee said. “Together with Pacific Group, who have invested a great deal of time and money into this project, the City of North Las Vegas has taken a prime piece of property across from the North Las Vegas VA Medical Center and transformed it into a true job creation zone that will become the premier destination in our region for medical research and care and fill a critical need in our community for generations. This piece of property is now valuable real estate and should add value to the Pacific Group’s portfolio.”

The project, designated as a Job Creation Zone, has now been named Helios, reflecting the focus of the project. Part world-class medical campus and part community gathering place to dine, shop and stay, Helios will offer the North Las Vegas community advanced and accessible healthcare hubs, and essential gathering places for locals to meet and mingle.

Slated for completion in phases over the next 7 to 10 years, this project is anticipated to include more than 2 million square feet of laboratory, research, and medical office space. More than 500,000 square feet of retail and restaurant space is also available, as well as 250 rooms for lodging. This project is anticipated to create over 10,000 jobs.

“This is a major milestone for North Las Vegas and the Southern Nevada Community; we’re excited to start bringing our vision for this project to life,” said Tony Sansone, Chief Financial officer of Pacific Group. “We are incredibly excited to continue working hand in hand with our partners at the City of North Las Vegas to deliver a best-in-class medical campus to serve the diverse needs of this community.”

North Las Vegas’ population has seen unprecedented growth in recent years, with its population increasing 132.3% since 2000, it is now Nevada’s third largest city and one of the fastest growing metros in the country. It is also Nevada’s largest minority-majority city. Southern Nevada’s population is expected to rise to 3.4 million residents by 2060. With such rapid expansion, the need for medical services is clear. Once completed, the Helios Medical Campus will mean many residents will no longer have to travel outside city limits for a doctor’s appointment.

With Q2 2022 Las Vegas metro medical office vacancy at a decade low and no new medical developments completed in the last 12 months, the 135 acre world-class Helios Health and Wellness Campus is poised to satisfy the surging demand of the medical community with the most unique and flexible opportunity to develop, own or lease their next center of excellence. With only one full-service hospital in North Las Vegas, Helios represents a giant leap forward in access to healthcare for residents and the greater Las Vegas Valley as a whole.

The founders of Helios also recognize that in addition to fulfilling a tremendous need for health and wellness in the area, thousands of nearby residents are sorely underserved in traditional retail needs as well, such as grocers, retailers, restaurants, fitness options, and traditional neighborhood services. Helios has dedicated over twenty acres to the development and fulfillment of those needs exclusively. Helios founders have partnered with commercial real estate brokerage firm Colliers International to begin discussions with prospective developers in search of the best suited partners. More information about leasing and partnership opportunities can be found at Helios.realestate.

Share article on social media or email:

One Hundred Five-Star Reviews on Google


News Image

“This great accomplishment is the result of an outstanding team effort to consistently put our patients first,” says Dr. Eric Cerrati.

A milestone worth celebrating was reached by Dr. Eric Cerrati and his Park City practice with the earning of 100 Google five-star reviews from his satisfied patients. Eric Cerrati, M.D. is double board certified and a leading expert in aesthetic and reconstructive facial plastic surgery. Recognizing that choosing facial cosmetic surgery can be a life-changing decision, Dr. Eric Cerrati treats all of his patients with the utmost respect and kindness. This approach, coupled with his five-star Google rating, attracts countless patients from across the country. Using his elite training and skill, he provides the most cutting-edge, advanced treatments available. Dr. Cerrati believes that the finest aesthetic outcomes are achieved through close doctor/patient collaboration, which is why he performs extensive consultations with all of his patients. He truly takes the time to carefully evaluate and develop a highly customized plan, focusing on all aspects of facial plastic surgery, including both surgical and non-surgical options, to help patients in the greater Salt Lake City area look his or her best. Facelifts, rhinoplasty, endoscopic browlift, blepharoplasty, facial fillers, Mohs reconstruction, scar revision and pediatric facial plastic surgery for vascular/congenital anomalies and more are offered by this talented plastic surgeon. Dr. Cerrati also provides patients with the most experience in craniofacial surgical procedures than other specialists in his area.

“This great accomplishment is the result of an outstanding team effort to consistently put our patients first,” says Dr. Eric Cerrati.

More about Dr. Eric Cerrati:

Dr. Eric Cerrati received his medical degree from the Medical University of South Carolina in Charleston, SC. His post-doctoral training included a 5-year residency in otolaryngology-head and neck surgery at NYU. Dr. Cerrati spent a significant amount of time working with Dr. Milton Waner, the founder of the Vascular Birthmark Institute of New York. This provided him with unique training in pediatric facial plastic surgery, addressing the rarest congenital anomalies. Following his residency, he completed a prestigious fellowship at the Facial Plastic Surgery Center in Chicago. Dr. Cerrati also served as the Director of Facial Plastic & Reconstructive Surgery at the University of Utah. As a leader in his field, Dr. Cerrati speaks at numerous conferences and is a contributor to many medical journals and textbooks. In addition to treating his patients, Dr. Cerrati is also the official facial plastic surgeon to the Utah Jazz, U.S. Ski and Snowboard Association, U.S. Speedskating, U.S. Bobsled and Skeleton Federation and the International Olympic and Paralympic Medical Committees. Dr. Eric Cerrati’s office is located at 1441 W. Ute Blvd, Ste 160 in Park City, UT. For more information, please visit http://www.drericcerrati.com or call (801) 497-6944.

Share article on social media or email:

Global Vaccine Market Exceeds $200 Billion: Kalorama Information Report


Sales increased from $127.6 billion in 2021 to an estimated $202.6 billion in 2022.

In 2022, the global market for vaccines is estimated to reach $202.6 billion. COVID-19 vaccines represent roughly two thirds of these revenues, according to Kalorama Information’s just-published market research report “The 2022 World Market for Vaccines“.

Kalorama’s report estimates total sales earned by vaccine manufacturers such as Astra Zeneca, Pfizer, Moderna and Glaxo and others, and projects revenues in various vaccine product segments to 2027. Arlington, Virginia-based Kalorama publishes reports in vaccines, devices and IVD. Companies use the Kalorama reports to benchmark market share, and investors and investment firms use reports to assess companies.

Exceeding two hundred billion dollars is significant when one considers this is up overall from $34.1 billion in 2017.

“COVID-19, Hepatitis and Shingles lead revenues, and these are adult vaccines.” said Bruce Carlson, Senior Vice President for Science and Medicine Group, owner of Kalorama Information. “Just six years ago the market was lead by pediatric vaccines but there was a trend even before COVID-19 toward adult vaccination.”

Infectious diseases are some of the deadliest diseases that pose significant risk to human life. Since the advent of the pandemic, scientists around the world have stepped up research and development of preventative vaccines that will hopefully be able to combat existing and new infectious disease threats.

Sales increased from $127.6 billion in 2021 to an estimated $202.6 billion in 2022.

Sales of adult vaccines are expected to increase at a faster pace than pediatric vaccines over the forecast period of this report, at 13% and 7% per year, respectively. Growth is largely supported by continued steady demand for booster doses in developed markets – namely United States, Western Europe, Australia and Japan – while the developing world continues to increase vaccine access and complete initial vaccine series and continued booster doses.

Through 2027, the report says growth will be fueled by favorable demographics (population growth, rising life expectancy), continued new product introductions, indication expansions for some products and rising usage, particularly in China and India. Markets outside the European and U.S. segments continue to grow, largely due to COVID-19 vaccination programs.

The report forecasts five years of COVID-19 and sees no reason to discontinue forecasts.    As Kalorama has indicated with COVID-19 testing markets all projections from academics are that the disease will be part of life for the next few years at least, requiring testing and vaccination to continue.

However the report urges that mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize. According to the CDC, vaccination rates for adults for both COVID and influenza significantly lag goals.

Competition in the market has increased over the years. Companies that compete in the vaccine market include Astra Zeneca, Pfizer, Moderna and Glaxo CSL, Johnson and Johnson, Dynavax, Inovio, Novavax, Merck & Co, Inc., Sanofi Pasteur, Bharat Biotech, and Takeda, among others.

Share article on social media or email:

Episcopal Relief & Development Partners with Episcopal Dioceses to Provide Emergency Assistance after Hurricane Ian


Damage due to Hurricane Ian in Fort Myers Beach, Florida
Photo Credit: U.S. Air National Guard photo by Senior Airman Jesse Hanson is licensed under CC BY-ND 2.0.

“The dioceses in Florida have worked hard over the past several years to prepare, which has allowed them to quickly respond with assistance where it is most needed,” said Lura Steele, Program Officer, Episcopal Relief & Development

Episcopal Relief & Development is partnering with the Episcopal dioceses of Southwest Florida and Florida to provide supplies and direct financial assistance to people affected by Hurricane Ian.

Over 100 people have been killed by Hurricane Ian, a Category 4 storm that made landfall in Florida on Wednesday, September 28, 2022. Thousands of people remain without power and many do not have access to clean drinking water as officials continue to survey the damage to homes and businesses.

With Episcopal Relief & Development’s support, the Diocese of Southwest Florida is providing direct financial assistance in the counties hardest hit by the storm. Local communities will use the aid to purchase gas and groceries, and for other special needs as they arise.

The Diocese of Florida, in partnership with Episcopal Relief & Development, is distributing blankets and sleeping bags and providing direct financial assistance to unhoused people and storm survivors. They will also work to replenish local food pantries and damaged community garden spaces that provide fresh food to communities affected by poverty.

“As power is being restored in some areas and roads are being cleared, the extent of the damage is becoming more clear,” said Lura Steele, Program Officer, US Disaster Program, Episcopal Relief & Development. “The dioceses in Florida have worked hard over the past several years to prepare, which has allowed them to quickly respond with assistance where it is most needed, both in the short-term and in the years to come.”

Episcopal Relief & Development US Disaster Program staff are working closely with partners throughout Florida as they continue to identify ways to collaborate in meeting needs created by the hurricane.

Please continue to pray for everyone who has been affected by Hurricane Ian. Donations to Episcopal Relief & Development’s Hurricane Relief Fund will provide additional emergency relief in communities impacted by storms such as Ian.

ABOUT EPISCOPAL RELIEF & DEVELOPMENT

For over 80 years, Episcopal Relief & Development has been working together with supporters and partners for lasting change around the world. Each year the organization facilitates healthier, more fulfilling lives for more than 3 million people struggling with hunger, poverty, disaster and disease. Inspired by Jesus’ words in Matthew 25, Episcopal Relief & Development leverages the expertise and resources of Anglican and other partners to deliver measurable and sustainable change in three signature program areas: Women, Children and Climate.

Share article on social media or email:

Researchers from Indiana University Validate Adaptive Testing Technologies’ CAT-SUD-E Computerized Adaptive SUD Scale for Screening, Measurement, and Diagnosis


News Image

Based on research, the CAT-SUD-E assessment tool provided a more complete characterization of SUD in both diagnostic classification and severity measurement.

A new research study published in Drug and Alcohol Dependence Reports reveals that an enhanced measure of the Computerized Adaptive Test for Substance Use Disorder (CAT-SUD), the CAT-SUD-Expanded (CAT-SUD-E), harmonizes information from mental health, trauma, social support, and traditional SUD items to provide a more complete characterization of SUD and provides both diagnostic classification and severity measurement. Both tools are part of the CAT-MH™ suite of mental and behavioral health assessments, developed by Adaptive Testing Technologies.

Substance use disorders (SUDs) are a public health emergency1, where most people with SUDs do not receive treatment for their SUDs and related mental health disorders2. Identifying those in need is a major barrier to receiving treatment3. SUD identification and treatment is predicated on accurate diagnoses, monitoring changes in risk and severity over time, and effective, timely interventions, targeted at the identified SUDs4.

The CAT-SUD, an adaptive test based on multidimensional item response theory, has been expanded to a new measure, CAT-SUD-E, to include 7 specific Diagnostic and Statistical Manual, 5th edition (DSM-5) defined SUDs. The CAT-SUD-E quickly produces results similar to lengthy structured clinical interviews for overall SUD and substance-specific SUDs, with high precision and accuracy, through a combination of fixed-item responses for diagnostic classification and adaptive SUD severity measurement. Participants were asked if they had used any of the following substances during the selected timeframe and then again, separately for lifetime use: alcohol, cannabis/marijuana/spice, nicotine (vaping, smoking, chewing), opioids, cocaine/crack, methamphetamines/amphetamines, hallucinogens, and sedatives. For each substance selected for each timeframe (e.g., past 30 days and lifetime), 5 questions, based on DSM-5 criteria, were asked.

Based on research conducted by study lead author, Leslie A. Hulvershorn, MD, MSc, Interim Co-Chair, Department of Psychiatry, Director, Division of Child and Adolescent Psychiatry, Associate Professor of Psychiatry, Indiana University School of Medicine, and Robert Gibbons, Ph.D., Blum-Riese Professor at the University of Chicago, the CAT-SUD-E assessment tool provided a more complete characterization of SUD in both diagnostic classification and severity measurement. Specifically:

· Adults completed CAT-SUD-E and structured diagnostic interviews

· CAT-SUD-E accurately predicted current and lifetime SUD diagnoses

· Median CAT-SUD-E completion time was less than 4 minutes

· Information is synthesized from multiple domains to assess SUD more comprehensively

“We have developed a new approach for the diagnostic screening and measurement of SUD that builds on our earlier work in adaptive measurement of SUD,” said Dr. Hulvershorn. “Our methodology synthesizes information from multiple related domains providing a more comprehensive measure of SUD and adds to that current and lifetime overall and substance-specific SUD diagnoses.”

About the Study

The study included 275 Community-dwelling adults (ages 18–68) who responded to public and social-media advertisements. Participants virtually completed both the CAT-SUD-E and the Structured Clinical Interview for DSM-5, Research Version (SCID) to assess the validity of the CAT-SUD-E in determining whether participants met criteria for specific DSM-5 SUDs. Diagnostic classifications were based on 7 SUDs, each with 5 items, for current and lifetime SUDs.

About Adaptive Testing Technologies

Adaptive Testing Technologies (ATT) is the leader in the design, testing, and implementation of large-scale, cloud-based mental health assessment tools based on Computerized Adaptive Testing (CAT) and Computerized Adaptive Diagnostic (CAD) technologies. These tools are utilized by health professionals to assess a variety of mental health conditions – including depression, anxiety, mania, psychosis, PTSD, substance use disorder, suicide risk, ADHD, and assess Social Determinants of Health. The CAT-MH™ and K-CAT® represent the first and only validated, comprehensive, multidimensional item-response-theory-based adaptive screening and measurement systems in the world. They provide levels of precision and accuracy that is far beyond what can be achieved using traditional fixed-length mental health assessment scales and can be administered anywhere at any frequency, in or out of the clinic, to any sized population. ATT’s tools are currently being utilized in emergency departments, psychiatric and primary care clinics, telemedicine, student health clinics, perinatal medicine clinics, child welfare settings, substance use disorder programs, federal and state mental health programs, employee assistance programs, and the judicial system. The tools are available worldwide and are currently being used worldwide.

###

MEDIA CONTACT:

Hannah Wulczyn, MPA

Adaptive Testing Technologies

mailto:hwulczyn@adaptivetestingtechnologies.com [hwulczyn@adaptivetestingtechnologies.com __title__ null]

312.878.6490, Ext. 505

1 Haffajee and Frank, 2018

2 Creedon and Lê Cook, 2016

3 Priester et al., 2016

4 Substance Abuse and Mental Health Services Administration (US), 2016

Share article on social media or email:

VPL Launches Data & Analytics Module to Give Healthcare Providers On-Demand Access to their Supply Chain Data


VPL Percept

VPL Percept

“Due to hidden margins, most health systems are overspending by at least 20% for inbound freight and 30% for outbound. VPL Percept provides visibility and transparency, revealing numerous cost savings opportunities and giving healthcare providers complete control over their supply chain operations.”

VPL, an industry leader in software technology solutions for healthcare systems, has just launched an enhanced version of their latest supply chain solution—VPL Percept™.

Predicated on the fact that healthcare providers struggle to gain a comprehensive view of all data associated with how products move into and throughout the healthcare system, VPL Percept was developed to give health systems on-demand access to all data related to supply chain and freight management operations. With the data and analytics-specific module, hospitals can reduce missed charges, optimize freight expense, and take full advantage of contract pricing as well as reimbursement opportunities.

“We noticed a trend of customers frequently asking their customer success manager to provide supply chain data during a business review, email, or monthly touchpoint,” says Eric McGlade, CEO and Co-Founder at VPL. “With VPL Percept, our customers will now have immediate insight into their supply chain freight spend and can even watch trends over time.”

With simple implementation and adoption, VPL Percept can target and monitor customers’ business initiatives with readily available data, drive internal conversations about missed savings opportunities on outbound shipments, identify unnecessary supplier fees, and optimize supplier compliance.

“Due to hidden margin models, most health systems are overspending by at least 20% for inbound freight and at least 30% for outbound freight,” says McGlade. “VPL Percept provides visibility and transparency into inbound and outbound freight, revealing numerous cost savings opportunities and giving healthcare providers complete control over their supply chain operations.”

On-demand access to actionable data, insights, and analytics are a key differentiator for VPL in the market and a direct benefit of their technology-focused approach. To explain more about what VPL Percept has to offer health systems, VPL hosted a 30-minute educational webinar on Wednesday, October 5 at 12pm ET. You can access the on-demand recording here. You can also read their blog about the importance of data and analytics in the healthcare supply chain here.

About VPL

By making the procurement-through-fulfillment processes smarter and more profitable, VPL is creating a new supplier dynamic whereby customers benefit from reduced costs, better insights, and increased transparency and efficiency. The industry’s only Smart Supply Chain Platform automates inbound and outbound shipping, unlocks visibility into the status of critical shipments, and identifies cost-savings opportunities for all of healthcare including IDNs, critical access, outpatient, and pharmacy. With more than 700 hospitals pharmacies, and ambulatory surgery centers, 6,000+ suppliers, and a 97% customer retention rate, it’s clear that VPL is the company the healthcare industry trusts to deliver savings, insights, and peace of mind. To learn more or to schedule a demo, visit the company’s website at http://www.getvpl.com.

Share article on social media or email:

Genedata Biologics Usage Expanded by Sanofi for Platformization of HT Multi-Specific Antibody Engineering


News Image

“We chose Genedata Biologics to support our quickly growing biopharmaceutical R&D operations and enable scientific innovation, including R&D of novel modalities such as bi- and multi-specifics and other next-gen therapeutics.” Rebecca Sendak, SVP of Global Large Molecules Research Platform at Sanofi

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Sanofi has expanded the use of Genedata Biologics® to new sites, groups, and application areas, including high-throughput engineering of next-generation multi-specific antibody therapeutics.

“We chose Genedata Biologics to support our quickly growing biopharmaceutical R&D operations and enable scientific innovation, including R&D of novel modalities such as bi- and multi-specifics and other next-gen therapeutics,” said Rebecca Sendak, Ph.D., Senior Vice President of Global Large Molecules Research Platform at Sanofi.

Genedata Biologics is used by major biopharma R&D organizations as a backbone for integrating globally operating research groups. Due to its flexible and scalable architecture, it facilitates the onboarding and integration of new R&D groups.

A key driver for extending the use of Genedata Biologics was the ability of the platform to implement fully automated end-to-end processes for generating rich data packages around innovative multi-specific antibody therapeutics. In addition to acting as an automation platform, Genedata Biologics provides a foundation of structured and accessible data that can feed into AI/ML workflows.

The Genedata Biologics foundation is complemented with other Sanofi enterprise systems and together they contribute to optimizing overall R&D operations by:

a)    enabling users to monitor program performance, resource and project planning, and task prioritization.

b)    providing a means for scientists, managers, and executives to have real-time access to data, which is the basis for systematic and transparent decisions on the biotherapeutic candidates to be progressed to the clinic.

“We are pleased that our long-term partner Sanofi continues to expand their usage of Genedata Biologics,” said Othmar Pfannes, Ph.D., CEO of Genedata. “The digital transformation of biopharmaceutical R&D is continuing at a rapid pace as companies strive to better organize and analyze their R&D data. We are excited that our technology is helping Sanofi and our other partners to develop innovative biotherapies faster.”

More details on the use of Genedata Biologics at Sanofi can be found in the mAbs Journal (Furtmann et al., An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics) or at http://www.tandfonline.com/doi/full/10.1080/19420862.2021.1955433.

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn| Twitter| YouTube

________________________________________

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Akeso Occupational Health Partners with Bizmatics to Minimize the Risk of Work-Related Injuries and Reduce Healthcare Costs


“We selected PrognoCIS for its Occupational Health focus and features, its modern extensible architecture & ability to support our “clinic-in-a-box” vision of providing all the capabilities we need to service our patients and employers effectively,” said Shankar Rao, CIO, Akeso Occupational Health.

Bizmatics Inc (the makers of PrognoCIS EHR software) and the leading provider of clinical and business productivity software and services for ambulatory medical clinics, has partnered with Akeso Occupational Health, the complete workplace resource with 15 California based locations. Akeso’s clients include Federal, State, County and Fortune 500 companies.

The Akeso Clinic Excellence Solution, ACES, powered by PrognoCIS, offers a full scope of Occupational Medicine services designed to minimize the risk of work-related injury, reduce healthcare costs, minimize lost work time and increase employee productivity.

The digital platform provides the end-to-end capabilities to engage all the constituents – Patients, Providers, Employers, Care Delivery Network and Payers from Scheduling through Revenue Cycle Management.

Key features include:

· Speedy Self-Service tablet-based Check-In

· Clinical Workflows that are efficient and have incorporated clinical best practices

· Real-time integration with the care delivery network that includes Laboratories, Radiologists and other partners to ensure quick turnaround of orders

· Quick checkout with all necessary documentation being provided to the patient and employer electronically in real-time

· An integrated telemedicine offering that allows the providers to deliver effective care in a virtual setting

· Anytime, anywhere access to required information and transactions via our portals and mobile apps

The platform continues to be enhanced with market leading features for employers and case adjuster including online scheduling, real-time visit and case status and analytical insights into the service and care delivery.

“Built with a focus on flexibility and customization, PrognoCIS is designed to fit the needs of even the most complex workflows” said Marc Keller, EVP, Bizmatics Inc. “The ultimate benefits of developing an EHR system is not just benefits to the providers but also to patients, the employers, employees and healthcare professionals”, he added further.

We selected PrognoCIS for its Occupational Health focus and features, its modern extensible architecture and its ability to support our “clinic-in-a-box” vision of providing all the capabilities we need to service our patients and employers effectively said Shankar Rao, Chief Information Officer, Akeso Occupational Health. “Ultimately, any product must be complemented with the right implementation, technical and support services and PrognoCIS team has demonstrated their professionalism, their willingness to understand our unique needs and deliver a solution that will be foundational in transforming our business”, he stated.

About Akeso Occupational Health (http://www.akesomedical.com) Akeso Occupational Health develops occupational medicine clinic groups that improve injured worker outcomes through a focus on the patient and a commitment to better partnerships with the payor. The experts at Akeso believe the key to fixing the workers’ compensation system centers around a dedicated group of physicians committed to the right care, without financial incentives for over-treating injured workers. These highly skilled physicians are backed by a clinical organization that works more closely with the insurance carrier and employer to make sure that the right care is delivered in a timelier manner.

About Bizmatics: A Business Unit of Harris Computer

A leading EHR company, Bizmatics provides clinical and business productivity software and services to ambulatory medical clinics -small, large, and multi-specialty. Our cloud-based application, PrognoCIS is a HIPAA compliant, fully integrated software solution comprising of EHR, Occupational Medicine, Telemedicine, Practice Management, Medical Billing, and Patient Engagement tools.

Share article on social media or email:

Envision Pharma Group and Alucio™ Partner to Power Next-Generation Scientific Exchange for the Life Science Industry


News Image

“By combining Alucio’s Beacon scientific exchange platform and technology with Envision’s medical affairs experience and scientific content development expertise, a broader set of life science companies will have the ability to assemble, refine, and adapt their scientific content with ease.”

Envision Pharma Group (Envision) and Alucio today announced a global partnership to power impactful, scientific exchange and deliver additional value for life science customers.

By combining Alucio’s innovative Beacon scientific exchange platform and technology with Envision’s extensive medical affairs experience and scientific content development expertise, a broader set of life science companies will have the ability to assemble, refine, and adapt their scientific content with ease. Beacon is a modern content activation and healthcare professional engagement platform built specifically for medical science liaisons, medical affairs professionals, and market access teams.

Through this collaboration, Envision will provide strategic, insight-driven communications expertise with agile content development approaches to assist medical affairs and market access teams in taking full advantage of the Beacon platform and future Alucio technology products.

More broadly, this global partnership has the potential to transform current industry standards in stakeholder engagement by redefining best practice content development processes and leveraging technology to create powerful, personalized scientific exchanges. Through a user-centric approach, the companies will seek to enhance and integrate technology solutions that deliver real-time data and analytics to inform strategy and aid customer decision-making.

“Envision is a recognized, global leader within the medical affairs space. We are very excited about the potential of this partnership to bring the benefits of our modern scientific exchange platform to an even broader network and establish best practice in the context of content development, deployment, and engagement,” said Dave Gulezian, Alucio Co-Founder and Chief Executive Officer. “We also look forward to collaborating to identify new opportunities to address emerging customer needs.”

Envision’s Chief Executive Officer, Meg Heim, added, “We have been impressed with what Alucio has built with Beacon and the momentum they have generated within the medical affairs space. We’re equally excited to align our medical strategy, agile content development, and communications expertise with Alucio’s technology capabilities to further enhance our customers’ stakeholder engagement through a personalized, omni-channel approach.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: http://www.envisionpharmagroup.com

About Alucio

Alucio is dedicated to the development of innovative software applications specifically for the life sciences industry. Alucio’s flagship product, Beacon, is a modern, cloud-based scientific exchange platform that enhances scientific dialogue and engagement between life science companies and healthcare professionals. For more information, please visit the company’s website at http://www.alucio.io

Share article on social media or email:

Memorial Healthcare System Appoints Monica Puga Chief Nursing Executive


Monica Puga is Memorial Healthcare System’s chief nursing executive.

“Monica has a distinctive leadership vision for nursing and patient care delivery which, in these challenging healthcare times, I’m confident will help us advance on many fronts.” – Nina Beauchesne, FACHE, executive vice president and chief transformation officer at Memorial Healthcare System.

Monica Puga, RN, MSN, a nurse leader for nearly 20 years at Memorial Healthcare System, has been named chief nursing executive.

The new senior vice president will utilize a data-driven approach to enhance care delivery, workforce development, and drive innovation. “A large part of my role is care transformation and cross-continuum care redesign, which will enable us to remove inefficiencies and improve on our high-quality outcomes,” said Puga, a graduate of both Nova Southeastern and Barry universities. “Our people, culture, clinical excellence, and passion for innovation will improve the Memorial experience for patients, families, staff, and providers.”

Puga began her career at Memorial as a registered nurse in 2001, quickly advancing through a variety of clinical and administrative leadership positions that led to the executive suite. One of her first strategic initiatives will be replenishing, retaining, and recognizing a nursing staff impacted by COVID-19. Puga says she’ll begin by promoting workforce development programs that include more residency and fellowship opportunities, introducing innovative staffing models, and creating an environment that focuses on the health and wellness of the entire care team.

“Monica has a distinctive leadership vision for nursing and patient care delivery which, in these challenging healthcare times, I’m confident will help us advance on many fronts,” said Nina Beauchesne, FACHE, executive vice president and chief transformation officer at Memorial Healthcare System.

As she has for the past seven years, Puga will continue to oversee Memorial’s population

health initiatives and Care Coordination Center.

Puga succeeds Maggie Hansen, RN, who retired after nearly 40 years with the healthcare system.

# # #

Memorial Healthcare System is one of the largest public healthcare systems in the U.S. and a national leader in quality care and patient, physician, and employee satisfaction. It is highly regarded for a patient and family-centered approach that prioritizes multi-disciplinary

collaboration, research, innovation, and transparency.

A South Florida-based academic medical center, Memorial is committed to healing the body, mind, and spirit of those it cares for at six hospitals (including Joe DiMaggio Children’s Hospital), numerous primary, urgent, and 24/7 care facilities, a health specialty center, and nursing home.

For more information, visit mhs.net and connect on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

Share article on social media or email: